Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene

To evaluate the cardiovascular actions of kinins, we established a transgenic rat line harboring the human tissue kallikrein gene, TGR(hKLK1). Under the control of the zinc‐inducible metallothionein promoter, the transgene was expressed in most tissues including the heart, kidney, lung, and brain, and human kallikrein was detected in the urine of transgenic animals. Transgenic rats had a lower 24‐h mean arterial pressure in comparison with control rats, which was further decreased when their diet was supplemented with zinc. The day/night rhythm of blood pressure was significantly diminished in TGR(hKLK1) animals, whereas the circadian rhythms of heart rate and locomotor activity were unaffected. Induction of cardiac hypertrophy by isoproterenol treatment revealed a marked protective effect of the kallikrein transgene because the cardiac weight of TGR(hKLK1) increased significantly less, and the expression of atrial natriuretic peptide and collagen III as markers for hypertrophy and fibrosis, respectively, were less enhanced. The specific kinin‐B2 receptor antagonist, icatibant, abolished this cardioprotective effect. In conclusion, the kallikrein‐kinin system is an important determinant in the regulation of blood pressure and its circadian rhythmicity. It also exerts antihypertrophic and antifibrotic actions in the heart.

[1]  M. Salis,et al.  Dilated and failing cardiomyopathy in bradykinin B(2) receptor knockout mice. , 1999, Circulation.

[2]  P. McIntyre,et al.  Molecular characterisation of cloned bradykinin B1 receptors from rat and human. , 1999, European journal of pharmacology.

[3]  S. Wolfrum,et al.  Pharmacology and cardiovascular implications of the kinin-kallikrein system. , 1999, Japanese journal of pharmacology.

[4]  D. Ganten,et al.  Blood pressure reduction and diabetes insipidus in transgenic rats deficient in brain angiotensinogen. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Pesquero,et al.  Molecular biology of the kallikrein-kinin system: from structure to function. , 1998, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[6]  T. Kai,et al.  Inhibitory effects of a subdepressor dose of L-158,809, an angiotensin II type 1 receptor antagonist, on cardiac hypertrophy and nephropathy via the activated human renin-angiotensin system in double transgenic mice with hypertension. , 1998, Japanese circulation journal.

[7]  M. Printz,et al.  Bradykinin-induced reductions in collagen gene expression involve prostacyclin. , 1998, Hypertension.

[8]  Tomohiko Suzuki,et al.  Potential role of kallikrein in diurnal rhythms and perivascular distribution in rat pineal glands , 1998, Brain Research.

[9]  L. Chao,et al.  Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. , 1998, Hypertension.

[10]  L. Chao,et al.  Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats. , 1998, Human gene therapy.

[11]  R. Ritchie,et al.  Bradykinin blocks angiotensin II-induced hypertrophy in the presence of endothelial cells. , 1998, Hypertension.

[12]  T. Ikeda,et al.  Role of bradykinin-NO pathway in prevention of cardiac hypertrophy by ACE inhibitor in rat cardiomyocytes. , 1997, American journal of physiology. Heart and circulatory physiology.

[13]  N. Glorioso,et al.  Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. , 1997, Circulation.

[14]  S. Boyce,et al.  Effects of the bradykinin B1 receptor antagonist des-Arg9[Leu8]bradykinin and genetic disruption of the B2 receptor on nociception in rats and mice , 1997, Pain.

[15]  H. Katus,et al.  Transgenic animal models: new avenues in cardiovascular physiology , 1997, Journal of Molecular Medicine.

[16]  L. Chao,et al.  Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. , 1997, Hypertension.

[17]  O. Carretero,et al.  Effect of high salt intake in mutant mice lacking bradykinin-B2 receptors. , 1997, Hypertension.

[18]  D. Ganten,et al.  Proceedings of the Symposium ‘Angiotensin AT1 Receptors: From Molecular Physiology to Therapeutics’: TRANSGENIC RATS: TOOLS TO STUDY THE FUNCTION OF THE RENIN‐ANGIOTENSIN SYSTEM , 1996, Clinical and experimental pharmacology & physiology.

[19]  R. Ishida,et al.  Induction of cardiac angiotensinogen mRNA and angiotensin converting enzyme (ACE) activity in isoproterenol-induced heart injury. , 1996, Hypertension research : official journal of the Japanese Society of Hypertension.

[20]  S. Reuss.  Components and connections of the circadian timing system in mammals , 1996, Cell and Tissue Research.

[21]  Witte,et al.  ABPM-FIT and CV-SORT: an easy-to-use software package for detailed analysis of data from ambulatory blood pressure monitoring. , 1996, Blood pressure monitoring.

[22]  A. Clerk,et al.  Stimulation of phosphatidylinositol hydrolysis, protein kinase C translocation, and mitogen-activated protein kinase activity by bradykinin in rat ventricular myocytes: dissociation from the hypertrophic response. , 1996, The Biochemical journal.

[23]  L. Chao,et al.  Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypertensive rats. , 1996, Human gene therapy.

[24]  B. Waeber,et al.  Cardiovascular hypertrophy: role of angiotensin II and bradykinin. , 1996, Journal of cardiovascular pharmacology.

[25]  D. Ganten,et al.  Transgenic rats: tools to study the function of the renin-angiotensin system. , 1996, Clinical and experimental pharmacology & physiology. Supplement.

[26]  D. Ganten,et al.  Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin–angiotensin-system gene expression and cardiovascular functions , 1995, Journal of hypertension.

[27]  C. Strader,et al.  Targeted Disruption of a B2 Bradykinin Receptor Gene in Mice Eliminates Bradykinin Action in Smooth Muscle and Neurons (*) , 1995, The Journal of Biological Chemistry.

[28]  D. Ganten,et al.  Chronic dexamethasone treatment suppresses hypertension development in the transgenic rat TGR(mREN2)27 , 1995, Journal of hypertension.

[29]  L. Chao,et al.  Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. , 1995, The Journal of clinical investigation.

[30]  T. Unger,et al.  Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. , 1995, Pharmacological reviews.

[31]  A. Dray,et al.  Kinins and kinin receptors in the nervous system , 1995, Neurochemistry International.

[32]  O. Jolobe.  Angiotensin-converting enzyme inhibitors. , 1995, British journal of hospital medicine.

[33]  G. Cuda,et al.  Angiotensin II maintains, but does not mediate, isoproterenol-induced cardiac hypertrophy in rats. , 1994, The American journal of physiology.

[34]  L. Chao,et al.  Human tissue kallikrein induces hypotension in transgenic mice. , 1994, Hypertension.

[35]  B. Janssen,et al.  Suprachiasmatic lesions eliminate 24-h blood pressure variability in rats , 1994, Physiology & Behavior.

[36]  D. Ganten,et al.  Transgenic rats: new experimental models for the study of candidate genes in hypertension research. , 1994, Annual review of physiology.

[37]  W. Linz,et al.  Bradykinin prevents left ventricular hypertrophy in rats , 1993, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[38]  A Mattes,et al.  Circadian blood pressure variation in transgenic hypertensive rats. , 1993, Hypertension.

[39]  J. Higaki,et al.  Role of Cardiac Angiotensin II in Isoproterenol‐Induced Left Ventricular Hypertrophy , 1992, Hypertension.

[40]  W. Linz,et al.  A specific B2‐bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril , 1992, British journal of pharmacology.

[41]  K. Bhoola,et al.  Bioregulation of kinins: kallikreins, kininogens, and kininases. , 1992, Pharmacological reviews.

[42]  K. Shimamoto,et al.  Immunoassays for the determination of human tissue kallikrein (TK) in different body fluids based on monoclonal antibodies. , 1992, Agents and actions. Supplements.

[43]  D. Ganten,et al.  Angiotensin and cell growth: a link to cardiovascular hypertrophy? , 1991, Journal of hypertension.

[44]  D. Ganten,et al.  Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene , 1990, Nature.

[45]  D. Diz.  Bradykinin and related peptides in central control of the cardiovascular system , 1985, Peptides.

[46]  R. Goldstein,et al.  Activation of protein formation and cell division by bradykinin and des-Arg9-bradykinin. , 1984, The Journal of biological chemistry.